Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference140 articles.
1. Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther. 2017. https://doi.org/10.2147/OTT.S139336.
2. Cook SA, Tinker AV. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00347-4.
3. Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther. 2015. https://doi.org/10.1124/jpet.114.222448.
4. US Food and Drug Administration (FDA). Talzenna (talazoparib): US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf. Accessed 10 Aug 2022.
5. Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMA). Summary of product characteristics: olaparib. 2019. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Accessed 10 Aug 2022.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献